

Anti-E2F1 p-Ser364 antibody, mouse monoclonal (#2)

71-151 100 μg

Shipping and Storage: Shipped at 4°C or -20°C and stored at -20°C.

Immunogen: A synthetic peptide corresponding to a sequence of human E2F1 protein including and surrounding phospho-Ser364

Form: Purified IgG 1 mg/ml in PBS- with 50% glycerol

Purity: Mouse monoclonal antibody (clone #2) specific to the human E2F1 protein phosphorylated at Ser364. Produced in serum-free medium and purified under mild conditions

Isotype: IgG2b κ

Reactivity: Human E2F1 protein phosphorylated at Ser364. Not tested with other species.

Applications

1. Western blotting (~1 ug/ml)

2. ELISA

Not tested for other applications.

Background: E2F1 is a member of E2F group of proteins that share common structural and functional domains and plays a major role during the G1/S transition in the mammalian cell cycle as a transcriptional factor (1). E2F1 is regulated during cell cycle progression. It is phosphorylated at Ser364 by Chk2 kinase in response to DNA damage, stabilized, mobilized to nucleus and activated as a transcription factor (2). It induces apoptosis by activating transcription of the p53 homolog, p73 (3). E2F1 protein consists of 437 amino acids with a molecular mass of 46 kDa.

Data Link UniProtKB/Swiss-Prot Q01094 (E2F1_HUMAN)

References

- 1. Trimarchi JM & Lees JA "Sibling rivalry in the E2F family" $Nat\ Rev\ Mol\ Cell\ Biol\ 3:11-20(2002)\ PMID:\ \underline{11823794}$
- 2. Stevens C et al "Chk2 activates E2F-1 in response to DNA damage" Nat Cell Biol 5:401-409 (2003) PMID: 12717439
- 3. Irwin M *et al* "Role for the p53 homologue p73 in E2F-1-induced apoptosis" Nature **407**:645-648 (2000) PMID: <u>11034215</u>

Figure. Identification of E2F1 protein phosphorylated at p-Ser364 with monoclonal antibody (#2)

MCF cells were grown in the absence (lane 1) or in the presence of etoposide at 10 μ M for 16 h (lanes 2 & 3). Crude lysates were prepared and analyzed by Western blotting (lane 3) with the antibody #2 or immunoprecipitated by pantropic anti-E2F1 antibody followed by Western blotting with the antibody #2.

